Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jo Shorthouse

London, U.K
Jo Shorthouse is features editor for Scrip Intelligence and manages the Scrip 100 publication. Jo has covered the biopharmaceutical industry and related service industries since 2008 when she edited Good Clinical Practice journal followed by Scrip Clinical Research. Before this, she worked at various publications covering topics such as chemical logistics, the advertising industry and the property market.
Advertisement
Set Alert for Articles By Jo Shorthouse

Latest From Jo Shorthouse

What Brexit Effect? UK Biotech Start-Ups Reach Record Numbers

With UK biotech venture capital investment at its highest level to date, biotech company building is showing no let up, with almost half of all UK biotech companies formed within the last three years.

United Kingdom Financing

Imara Broadens Hematology Horizons With $63m Fundraising

Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II drug candidate into related blood disorders such as beta thalassemia.

Commercial Financing

German Government Joins Superbug Fight With €40m CARB-X Investment

Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.

Infectious Diseases Germany

Merck Makes Its Debut In Pain With Pioneering New Analgesic Class

Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.

Innovation Deals

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

Deals Business Strategies

Lundbeck Leads $50m Fund Raise For CRISPR Microbiome StartUp

A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.

Financing StartUps and SMEs
See All
Advertisement
UsernamePublicRestriction

Register